Junshi Biosciences Doses First Patient in Phase 3 Liver Cancer Trial
Junshi Biosciences dosed the first patient in a Phase 3 trial of JS207-JS007 for advanced liver cancer.
Related stories
TMX Group Q3/26 Net Income Falls 12% to CAD 105.8 Million
Q3/26 revenue rose 17% to CAD 491.1 million.
M impact | EQUITY | Oct 29, 2026, 11:14 PM UTC
TMX Group Reports Third-Quarter 2026 Results
TMX Group reported third-quarter 2026 revenue of $491.1 million, up 17%.
M impact | EQUITY | Oct 29, 2026, 11:14 PM UTC
TMX Group Reports Lower Q3 Net Profit and Higher Revenue
TMX Group reported lower net profit and higher revenue in Q3/26.
M impact | EQUITY | Oct 29, 2026, 11:07 PM UTC
TMX Group Q3 revenue reaches C$491.1 million
Revenue was C$491.1 million, versus the IBES estimate of C$476.1 million.
M impact | EQUITY | Oct 29, 2026, 11:04 PM UTC
SanDisk Reports Fiscal Q1 2027 Results, Guides Higher and Announces Forward Stock Split
SanDisk reported revenue of $11.0 billion, up 23% sequentially, and GAAP net income of $8.1 billion, or $52.60 per diluted share. Non-GAAP diluted EPS was $49.51 versus analyst exp
M impact | EQUITY | Oct 29, 2026, 11:02 PM UTC
Richards Group Reports Q3 Revenue Up 2%, Gross Margins Up 7%
Revenue rose 2% primarily from acquisitions, while gross margins increased 7%. Healthcare benefited from DermapenWorld and PharmaSystems; packaging demand remained soft.
M impact | EQUITY | Oct 29, 2026, 11:02 PM UTC